

Clinical Trial	Location(s)	Current Status	# of Patients	Taking sirolimus allowed?	Travel funds available?	Study Coordinator(s)
<b>Observational &amp; Registry Studies</b>						
<b>NIH</b>	Bethesda, MD	Ongoing	NA	NA	Yes	<b>Tania Machado, tania.machado@nih.gov</b> <b>Sara Hauff, sara.hauff@nih.gov</b> (301)-496-3632 (o) (301)-648-5674 (c)
<b>NDRI</b>	Any	Ongoing	NA	NA	NA	<b>Anne McKenna, amckenna@thelamfoundation.org</b> (513) 777-6889
<b>MIDAS</b>	Palo Alto, CA, Denver, CO, Jacksonville, FL, Atlanta, GA, Chicago, IL, Boston, MA, Ann Arbor, MI, Rochester, MN, St. Louis, MO, Rochester, NY, Cincinnati, OH, Cleveland, OH, Portland, OR, Philadelphia, PA, Charleston, SC, Nashville, TN, Dallas, TX, Houston, TX; Salt Lake City, UT, Seattle, WA	Enrolling through 04/2020	300	YES	NO	<b>All Sites: Susan McMahan, susan.mcmahan@uc.edu</b>  (513) 558-4376 (o)
<b>Interventional Studies</b>						
<b>COLA</b>	Boston, MA & Bethesda, MD	Enrolling through 06/2018	12	NO	YES	Boston, MA: <b>Shefali Bagwe, sbagwe@bwh.harvard.edu</b> (857) 307-0784 (o) Bethesda, MD: <b>Tania Machado, tania.machado@nih.gov</b> (301)-496-3632 (o) (301)-648-5674 (c)
<b>LAMP-1</b>	Charleston, SC & New York, NY	Enrolling through 03/2018	20	YES	YES (minimal, SC only)	Charleston, SC: <b>Kimberly Brown, brownkl@muscc.edu</b> (843)-792-6474 (o) New York, NY: <b>Laura Fonseca, lf2560@cumc.columbia.edu</b> (212)-305-3745 (o)
<b>MILED</b>	Palo Alto, CA, Denver, CO, Atlanta, GA, Chicago, IL, Boston, MA, St. Louis, MO, Cincinnati, OH, Cleveland, OH, Philadelphia, PA, Nashville, TN, Seattle, WA	Enrolling through 06/2020	60	NO	YES	<b>All Sites: Sue McMahan, susan.mcmahan@uc.edu</b> (513) 558-4376 (o)
<b>SLAM-2</b>	Houston, TX, Palo Alto, CA, Chicago, IL, Boston, MA, Cincinnati, OH, Bethesda, MD	Enrolling through 07/2018	22	NO	YES	<b>All sites: Melissa Brock, mbrock@bcm.edu</b> (713) 873-8772 (o)



The purpose of this document is to summarize all currently enrolling clinical research trials and studies for LAM patients. For more detailed information about all ongoing, currently enrolling, and upcoming clinical research please visit [TheLAMFoundation.org](http://TheLAMFoundation.org) and review the Current Clinical Trials and Studies page.

## Ongoing Trials and Studies

These trials include observational and registry studies.

**National Institutes of Health (NIH)** - Study of the Disease Process of LAM

Principal Investigator: Joel Moss, MD, PhD

**National Disease Research Interchange (NDRI)** – Tissue Donation

**MIDAS** - Multi-Center International Durability and Safety of Sirolimus in LAM

Principal Investigator: Francis X. McCormack, MD

## Interventional Trials and Studies

These trials require patients to take an investigational research drug or placebo pill.

**A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC (COLA)**

Principal Investigator: David J. Kwiatkowski, MD, PhD

**LAM Pilot Study with Imatinib Mesylate (LAMP-1)**

Principal Investigator: Jeanine D'Armiento, MD, PhD & Charlie Strange, MD

**Multicenter Interventional LAM Early Disease (MILED)**

Principal Investigator: Francis X. McCormack, MD

**Safety and Efficacy of Saracatinib in Subjects with LAM (SLAM-2)**

Principal Investigator: Tony Eissa, MD